Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Obesity drugs

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Feb 22, 2024 3:20pm

68 Views

Post# 35894107

RE:RE:RE:RE:Obesity drugs

There is no more patent on Egrifta. Any market more interesting than this HIV population will attarct generic competition. F8 was supposed to fix that fo Nash potnetial. Who would partner for Nash with no patent protection. That's F8 and the FDA seems to think that the patient benefits may not justify a patent extention. Because you know they will pull F4 from the market since that would prevent generics from taking that route.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec